In August 2018, it was announced that Xhale - pulse oximetry sensor maker - had been acquired by Dutch firm Koninklijke Philips. Xhale will operate a a subsiduary of the larger firm. Formerly known as Exhale Diagnostics Inc,Xhale organizes operation around exhaled breath and novel vapor analysis technology. Grounded in intellectual property and patents licensed from the University of Florida, Xhale, Inc. is developing and commercializing patient-centric monitoring solutions for the healthcare industry. Focused on developing two broad technology platforms, through its Xhale Smart, Inc. subsidiary, Xhale is developing a medication adherence monitoring technology â the SMART® Adherence System â designed to verify, monitor, report, and improve adherence to medication regimens in clinical trials. The SMART® Adherence System is the only technology designed to offer definitive and noninvasive monitoring of medication adherence in near real-time, utilizing exhaled breath to confirm that medication has been taken as directed. Through its Xhale Assurance, Inc. subsidiary, Xhale is developing a patient monitoring technology, the Assurance® platform, designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhaleâs first product based on this technology, the Assurance® Alar One-Sense⢠pulse oximetry sensor, received marketing clearance in the United States. The Assurance® Alar One-Sense⢠pulse oximetry sensor is a disposable sensor placed on a patientâs nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor.. Tthe company offers Self-Monitoring And Reporting Therapeutics (SMART) technology, which enables the creation of a breath-detectable version of any pharmaceutical drug; and clinical trials monitoring system that provides a method of proving that clinical trial participants took the right medication and the right dose at the right time during a clinical trial. It also provides portable road-side system, which is used for evidentiary breath ethanol testing; drug metabolism/enzyme competency monitoring system that allows physicians, clinics, and hospitals to perform breath-based point-of-care analysis of a patient's ability to properly metabolize a new medication; and breath-based IV-anesthetic monitors, which are designed for monitoring and maintaining set blood levels of IV-anesthetic agents based on exhaled breath. In addition, the company offers desk-top and handheld breath-based diagnostic system that provides point-of-care testing replacing conventional blood and urine-based diagnostic tests; breath-based human stress/health biomonitor, a small breath-analysis monitor, which is tuned to particular biomarkers of health and stress with medical and biodefense/military applications; and hand washing compliance system that monitors and improves hand washing compliance to help eliminate hospital acquired infections. Its products are used in disease management, managed care, pharmaceutical clinical trials, medical, home, law enforcement, and industrial diagnostic markets applications. The company is based in Gainesville, FL with a laboratory facility in San Diego, CA; and a manufacturing facility in Bo